Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(14 sites)
United States
Augusta University Medical Center, Augusta, Georgia University of Chicago Comprehensive Cancer Center, Chicago, Illinois University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa Wayne State University/Karmanos Cancer Institute, Detroit, Michigan University of New Mexico Cancer Center, Albuquerque, New Mexico